{"commentary":{"count":16,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":16},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01863550\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT01863550","nct_id":"NCT01863550","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct01863550. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive bortezomib SC or IV on days 1, 4, 8, and 11 of courses 1-8 and days 1 and 8 of courses 9-12; lenalidomide PO daily on days 1-14; and dexamethasone PO daily on days 1, 2, 4, 5, 8, 9, 11, and 12 of courses 1-8 and days 1, 2, 8, and 9 of courses 9-12. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.","label":"Arm A (bortezomib, lenalidomide, dexamethasone)","type":"EXPERIMENTAL"},{"description":"Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16; lenalidomide PO daily on days 1-21; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.","label":"Arm B (carfilzomib, lenalidomide, dexamethasone)","type":"EXPERIMENTAL"},{"description":"Patients receive lenalidomide PO daily on days 1-21. Treatment repeats every 4 weeks for 24 courses in the absences of disease progression or unacceptable toxicity.","label":"Arm C (lenalidomide)","type":"EXPERIMENTAL"},{"description":"Patients receive lenalidomide PO daily on days 1-21. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.","label":"Arm D (lenalidomide)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2034-02-05","type":"ESTIMATED"},"conditions":["Plasma Cell Myeloma"],"enrollment":{"count":1087,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Bortezomib","type":"DRUG"},{"name":"Carfilzomib","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"},{"name":"Laboratory Biomarker Analysis","type":"OTHER"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Quality-of-Life Assessment","type":"OTHER"}],"last_update":"2026-10-05","lead_sponsor":"ECOG-ACRIN Cancer Research Group","official_title":"Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival (OS) for the maintenance analysis","timeFrame":"From the maintenance randomization to death due to any cause or, censored at the date last known alive, assessed up to 15 years"},{"measure":"Progression-free survival for the induction analysis","timeFrame":"From the induction randomization until the earlier of progression or death due to any cause, assessed up to 15 years"}],"references":[{"citation":"Kumar S, Jacobus S, Cohen A, Weiss M, Callander N, Singh A, Parker T, Green M, Thertulien R, Parsons B, Kumar P, Kapoor P, Rosenberg A, Dib E, Almquist D, Zonder J, Faber E, Wei Z, Anderson K, Lonial S, Richardson P, Orlowski R, Wagner L, Rajkumar SV. Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma. N Engl J Med. 2026 Jul 16;395(3):221-232. doi: 10.1056/NEJMoa2600157.","pmid":"42456135","type":"DERIVED"},{"citation":"Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E Jr, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.","pmid":"32866432","type":"DERIVED"}],"start_date":{"date":"2013-12-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT01863550"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct01863550"}